3 completed, 3 not yet recruiting, 3 recruiting, 1 active not recruiting. 2 Not applicable, 2 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Not yet recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
Follow Malignancies Multiple: new trials by email Literature Review of Malignancies Multiple trials Research Report on Malignancies Multiple
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PET/CT Imaging of GRPR Expression in Various Tumors GRPR PET/CT - Malignancies Multiple | Early Phase 1 | Not yet recruiting | Jewish General Hospital | 60 | 2026-11-01 | 2026-09-18 |
| Clinical Outcomes of Stroke in MalIgnanCy 1-year cumulative incidence of any recurrent stroke after the index event in patients with malignancy, overall and separately after index AIS and index ICH. - Stroke, Malignancies Multiple | Not yet recruiting | University of L'Aquila | 1000 | 2026-10-31 | 2026-10-26 | |
| Feasibility Pilot of AYA-PARTNER AYA-PARTNER Navigation Intervention - Cancer, Malignancies Multiple | Not applicable | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 30 | 2026-09-15 | 2026-09-18 |
| The Frequency of Anastomotic Leakage in Early and Delayed Oral Feeding Following Ileostomy Reversal Will be Compared Early oral feeding protocol, Delayed oral feeding protocol - Malignancies Multiple | Not applicable | Completed | Allied Hospital Faisalabad | 420 | 2026-03-30 | 2026-07-28 |
| Remote Vital Sign Monitoring in Palliative Care Patients Using a Wearable ECG Monitor Cancer, Malignancies Multiple | Recruiting | Our Lady's Hospice and Care Services | 120 | 2025-11-06 | 2026-04-06 | |
| Coronavirus Disease 2019 (COVID-19) Vaccination in Cancer Patients COVID-19 vaccine hesitancy and acceptance survey - Malignancies Multiple | Completed | Monika Joshi | 130 | 2021-08-30 | 2024-05-09 | |
| CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents., Patient-reported outcomes (PROs) - Cancer, Malignancies Multiple | Recruiting | University Health Network, Toronto | 5500 | 2020-01-17 | 2025-12-03 | |
| 9-ING-41 in Patients With Advanced Cancers 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin. - Cancer, Pancreatic Cancer | Phase 2 | Active not recruiting | Actuate Therapeutics Inc. | 350 | 2019-01-04 | 2026-04-03 |
| A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects BMS-986205, Itraconazole, Rifampin - Malignancies Multiple | Phase 1 | Completed | Bristol-Myers Squibb | 53 | 2017-11-22 | 2018-02-28 |
| Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies Anti-PD-1 antibody, Decitabine, Chemotherapy - Malignancies Multiple | Phase 1 / Phase 2 | Recruiting | Han weidong | 250 | 2016-05-01 | 2026-01-22 |
Neoplasms (7) · Bone Neoplasms (1) · Breast Neoplasms (1) · COVID-19 (1) · Colorectal Neoplasms (1) · Congenital Abnormalities (1) · Glioma (1) · Hemorrhagic Stroke (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Ischemic Stroke (1) · Kidney Neoplasms (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm Metastasis (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Lung Diseases (2) · Nervous System Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Bone Diseases (1) · Brain Diseases (1) · Breast Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Colonic Diseases (1) · Congenital Abnormalities (1) · Coronaviridae Infections (1)
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Decitabine (1) · Doxorubicin (1) · Drug Therapy (1) · Gemcitabine (1) · Irinotecan (1) · Itraconazole (1) · Lomustine (1) · Paclitaxel (1) · Patient Reported Outcome Measures (1) · Rifampin (1) · Taxes (1) · Tyrosine Kinase Inhibitors (1)
Actuate Therapeutics Inc. (1) · Allied Hospital Faisalabad (1) · Bristol-Myers Squibb (1) · Han weidong (1) · Jewish General Hospital (1) · Monika Joshi (1) · Our Lady's Hospice and Care Services (1) · UNC Lineberger Comprehensive Cancer Center (1) · University Health Network, Toronto (1) · University of L'Aquila (1)
United States (4) · Canada (2) · Belgium (1) · China (1) · France (1) · Ireland (1) · Netherlands (1) · Pakistan (1) · Portugal (1) · Spain (1)
Chunmeng Wang, Master (1) · Geoffrey Liu, MD, MSc (1) · Hejin Jia, Doctor (1) · Jacob Stein, MD (1) · Jing Nie, Doctor (1) · Jingdan Qiu, Doctor (1) · Kaichao Feng, Doctor (1) · Liang Dong, Master (1) · Lu Shi, Master (1) · Meixia Chen, Doctor (1) · Monika Joshi, MD (1) · Qian Mei, Doctor (1) · Wenying Zhang, Master (1) · Xiang Li, Master (1)
PMID 24327518, PMID 25895027, PMID 27191266, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29846250, PMID 30405781, PMID 30975030, PMID 31039052, PMID 31101621, PMID 31401903, PMID 31533931, PMID 31831767, PMID 31882719, PMID 31894292, PMID 33674274, PMID 33820822, PMID 35815408, PMID 41981308